Abstract 2129P
Background
Exercise in cancer patients can mitigate declines in physical and psychosocial function. However, low recruitment and retention for in-person exercise programs limit evidence-based program development for patients with advanced lung cancer. The study of a virtual intervention, that leverages on the emerging acceptance of virtual healthcare delivery, has the potential to overcome barriers of prior exercise studies.
Methods
Mitigation of decline with Virtual Exercise with Lung Cancer is an ongoing prospective single-arm feasibility study. Individuals with advanced lung cancer on systemic therapy were recruited to a 12-week virtual group exercise program, including aerobic and functional strength exercises, delivered twice weekly over Zoom by an exercise physiologist. Feasibility measures included accrual, attendance, exercise adherence, attrition, and adverse events. Efficacy measures and quality of life (QoL) were assessed at start and end of program. Patient demographics, treatment, and outcomes were collected via electronic medical records.
Results
Of 44 patients referred, 30 were eligible and enrolled, of which, 3 were lost to follow up, 1 withdrew, 16 completed and 10 continue to participate in the program. Baseline demographics of 26 active participants: median age 65.5 years old (range 39 – 88), female (n=12), ECOG 0/1 (n=24), adenocarcinoma (n=21), metastasis to brain (n=9), liver (n=4), bone (n=7), and on targeted therapy (n=19). Total attendance is 87% and adherence is 96%. Of those who completed the program, statistically significant changes in physical function were identified by the 6 minute walk test (median improvement of 147 meters p = 0.046), gait speed (p = 0.030), sit to stand (p = 0.004), and biceps curl repetitions (p = 0.001). No significant difference was found in QoL using the Functional Assessment of Chronic Illness Therapy-Lung (FACT-L) and -Fatigue (FACT-F) questionnaires. Participants found the program to be accessible and were very likely to recommend this program to a friend.
Conclusions
Preliminary results suggest that a virtual exercise program for patients with advanced lung cancer is feasible, with high attendance and adherence, and significant improvements in physical function.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Wang, K. Campbell.
Funding
BC Lung Foundation, BC Cancer Foundation.
Disclosure
Y. Wang: Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Merck, Takeda; Financial Interests, Institutional, Research Grant: AZ. P. Camp: Financial Interests, Other, Personal, Conducted evaluation: Carrier Sekani Family Services. Financial Interests, Coordinating PI, Institutional, Receive funding for operational and team grants: Canadian Institutes of Health Research. Financial Interests, Coordinating PI, Institutional, Receive funding for operating grants: BC Lung Foundation. J. Laskin: Financial Interests, Advisory Board, Personal, invited speaker: Roche Canada. Financial Interests, Invited Speaker, Personal, speaker at educational event: Pfizer. Financial Interests, Advisory Board, Personal, invited to national ad board: Takeda. Financial Interests, Research Grant, Institutional, Funding for a IIT: Roche Canada. K. Campbell: Financial Interests, Personal, Stocks/Shares: Abcellera; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer Canada. All other authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06